Sumitomo Pharma America, INC.

pharmaceutical company

Based in MA

🤖

AI Overview

With $550K in lobbying spend across 13 quarterly filings, Sumitomo Pharma America, INC is an active lobbying client. Their lobbying covers 2 issue areas. Active from 2021 to 2024.

$550K

Total Spend

Years Active

Firms Hired

Lobbyists Deployed

Issues Lobbied

Spending Trend

View as table

Year	Lobbying Spend
2021	$20K
2022	$200K
2023	$260K
2024	$70K

Issues Lobbied

Health Issues Medicare/Medicaid

Lobbying Firms

Impact Health Policy Partners

Lobbyists

Billy Wynne Alyson Lewis

Government Agencies Targeted

These are the government entities that Sumitomo Pharma America, INC. disclosed contacting in their lobbying filings.

HOUSE OF REPRESENTATIVESSENATEHealth & Human Services, Dept of (HHS)White House Office

View all agency pressure data →

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, Medicare/Medicaid

Issues relating to Medicare Part D reform, mental health, central nervous system disorders, and Parkinsons Disease.

Phase-in of Part D reform for low-income subsidy beneficiaries; H.R.5376, Build Back Better Act.

Phase-in of Part D reform for low-income subsidy beneficiaries; H.R. 5376, FY 2022 Budget Reconciliation; and H.R.2471, Consolidated Appropriations Act, 2022 (P.L. 117-103).